Clinical trial
SMD_FLAG-IDA_98: FLAG-IDA in Induction Treatment of High Risk Myelodysplastic…
NCT00487448 · PETHEMA Foundation, Other · Completed
Key facts
| NCT number | NCT00487448 |
|---|---|
| Title | SMD_FLAG-IDA_98: FLAG-IDA in Induction Treatment of High Risk Myelodysplastic Syndromes or Secondary Acute Myeloblastic Leukemia |
| Official title | FLAG-IDA Chemotherapy Induction Follow by Intensive Chemotherapy Postremission +/- Autologous Hemopoietic Stem Cell Transplantation or Bone Marrow Transplantation in Patients With High Risk Myelodysplastic Syndromes or Secondary Acute Myeloblastic Leukemia. |
| Acronym | FLAG-IDA |
| Lead sponsor | PETHEMA Foundation, Other |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Myelodysplastic Syndrome, Acute Myeloblastic Leukemia |
| Intervention type | Drug, Procedure |
| Interventions | Fludarabine, Cytarabine, G-CSF, Idarubicin, Peripheral blood stem cell transplantation, Bone marrow transplantation |
| Enrollment | 200 |
| Start date | Jul 1, 1998 |
| Primary completion | May 1, 2007 |
| Completion | Jun 1, 2007 |
| First posted | Jun 18, 2007 |
| Last update posted | Nov 19, 2008 |
| Countries | Spain |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: